Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Average: 2010-2020

Historic Equity Average for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2020 value amounting to $881.5 million.

  • Neurocrine Biosciences' Equity Average rose 60.51% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 60.51%. This contributed to the annual value of $881.5 million for FY2020, which is 57.75% up from last year.
  • According to the latest figures from FY2020, Neurocrine Biosciences' Equity Average is $881.5 million, which was up 57.75% from $558.8 million recorded in FY2019.
  • In the past 5 years, Neurocrine Biosciences' Equity Average ranged from a high of $881.5 million in FY2020 and a low of $343.5 million during FY2017.
  • In the last 3 years, Neurocrine Biosciences' Equity Average had a median value of $558.8 million in 2019 and averaged $622.3 million.
  • In the last 5 years, Neurocrine Biosciences' Equity Average declined by 7.08% in 2017 and then surged by 57.75% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Equity Average (Yearly) stood at $369.7 million in 2016, then declined by 7.08% to $343.5 million in 2017, then grew by 24.15% to $426.5 million in 2018, then surged by 31.04% to $558.8 million in 2019, then surged by 57.75% to $881.5 million in 2020.